2023ÄêÅ·Ö޷ΰ©´ó»á£¨ELCC£©½«ÓÚ2023Äê3ÔÂ29ÈÕ-4ÔÂ1ÈÕÔÚµ¤Âó¸ç±¾¹þ¸ùÒÔÏßÉÏÏßÏÂÏà½áºÏµÄÐÎʽ¾ÙÐС£±¾´ÎELCC´ó»á±¨µÀÓÉÖйú´ó½ר¼Ò×÷ΪµÚÒ»×÷Õß»òͨѶ×÷ÕßµÄEGFR-TKIÏà¹ØÑо¿¹²11ƪ£¬ÆäÖаüÀ¨µÏÍþÖÆµÏÍþ¹ú¼Ê×ÔÖ÷´´ÐµÏÍþ¹ú¼Ê¼×»ÇËá°¢ÃÀÌæÄáÆ¬(ÉÌÆ·Ãû£º°¢ÃÀÀÖ?)Ïà¹Ø³É¹û5ƪ£¬Õ¼×ÜÆªÊýµÄ45%£¬ÔÚËùÓÐEGFR-TKIÖÐÃûÁеÚÒ»£¬ÔÚ¹ú¼ÊÎę̀·¢³öÖйúÔ´´ÐµÏÍþ¹ú¼Ê×îÇ¿Òô£¡
ELCCÊǷΰ©ÁìÓò±¶ÊܹØ×¢µÄÖØÒªÑ§Êõ»áÒéÖ®Ò»£¬ÓÉÅ·ÖÞÖ×ÁöÄÚ¿ÆÑ§»á£¨ESMO£©Óë¹ú¼Ê·Î°©Ñо¿Ð»á£¨IASLC£©ÁªºÏ¾Ù°ì£¬ÖÂÁ¦ÓÚ´Ù½ø¿ÆÑ§·¢Õ¹¡¢´«²¥½ÌÓýºÍÌá¸ßÈ«ÊÀ½ç·Î°©×¨¼ÒµÄÁÙ´²Êµ¼ù¡£±¾½ìELCCÄê»á£¬°¢ÃÀÌæÄá5ƪժҪÈëÑ¡£¬°üÀ¨3ƪÑо¿Êý¾ÝºÍ2ƪÑо¿Éè¼Æ£¬·Ö±ð´øÀ´ÔÚ·ÇСϸ°û·Î°©£¨NSCLC£©°ÐÏòÁªºÏ·ÅÁÆ¡¢¸¨ÖúÖÎÁƺ͸߼ÁÁ¿ÄÔ×ªÒÆÖÎÁÆ·½ÏòµÄ×îÐÂÑо¿½øÕ¹¡£
³£¹æÕªÒª
ÕªÒª±àºÅ£º18P
Stereotactic radiotherapy(SRT) in combination with Aumolertinib to treat intracranial oligometastatic Non-Small Cell Lung Cancer (NSCLC): An update of the phase II, prospective study
°¢ÃÀÌæÄáÁªºÏÁ¢Ì嶨Ïò·ÅÁÆ(SRT)ÖÎÁÆÂÄÚ¹Ñ×ªÒÆÐÔNSCLC£ºÒ»ÏîǰհÐÔIIÆÚÁÙ´²Ñо¿
×÷Õߣº·®•G/³Â¼ÑÑÞ½ÌÊÚ£¨¸´µ©´óѧ¸½ÊôÖ×ÁöÒ½Ôº£©
¼ò½é£º±¾Ñо¿£¨NCT04519983£©Ö¼ÔÚ̽Ë÷°¢ÃÀÌæÄáÁªºÏSRTÖÎÁÆÂÄÚ¹Ñ×ªÒÆÐÔNSCLCµÄÁÆÐ§ºÍ°²È«ÐÔ¡£¹²ÄÉÈë35Àý¾ßÓÐEGFRÃô¸ÐÍ»±äµÄÂÄÚ¹Ñ×ªÒÆ»¼Õߣ¬½ÓÊܰ¢ÃÀÌæÄá110mgÖÎÁÆ£¬Ö±µ½ÂÄÚ¼²²¡½øÕ¹£¬ÔÚÂÄڹѽøÕ¹ºó½ÓÊÜSRTÖÎÁÆ£¨32¨C40Gy£¬8Gy/f£©¡£Ö÷ÒªÖÕµãÊÇÂÄڿ͹ۻº½âÂÊ£¨iORR£©¡£Êý¾Ý½ØÖ¹Ê±£¬32Àý»¼Õß¿ÉÆÀ¹ÀÁÆÐ§£¬Ëæ·Ãʱ¼äΪ3-16¸öÔ¡£ËùÓв¡Ô°üÀ¨ÂÄÚºÍÂÍ⣩¶ÔÖÎÁƾù´ïµ½²¿·Ö»º½â£¨PR£©£¬ iORR´ï100%£»Î´·¢Éú¡Ý3¼¶²»Á¼Ê¼þ¡£
ÕªÒª±àºÅ£º97P
Aumolertinib as adjuvant therapy in postoperative EGFR-mutated stage I-III non-small cell lung cancer with high-risk pathological factors
°¢ÃÀÌæÄḨÖúÖÎÁƾßÓиßΣ²¡ÀíÒòËØµÄEGFRÍ»±äI-IIIÆÚNSCLC
×÷ÕߣºÉòΤÓð½ÌÊÚ£¨Äþ²¨ÊÐÒ½ÁÆÖÐÐÄÀî»ÝÀûÒ½Ôº£©¡¢Éòº£²¨½ÌÊÚ£¨Äþ²¨ÊеڶþÒ½Ôº£©
¼ò½é£º±¾Ñо¿¹²ÄÉÈë115ÀýÍêÈ«Çгý¡¢I-IIIÆÚ¡¢º¬ÊµÌ塢΢ÈéÍ·»ò¸´ÔÓÏÙÌå³É·ÖµÄ·ÎÏÙ°©»¼Õߣ¬·ÖΪA×飺EGFRÑôÐÔ£¬½ÓÊܰ¢ÃÀÌæÄá110 mgÖÎÁÆ£¨n=45£©£¬B×飺EGFRÑôÐÔ£¬¹Û²ì£¨n=25£©£¬C×飺EGFRÒõÐÔ»òδ֪£¬¹Û²ì£¨n=45£©¡£Ö÷ÒªÖÕµãÊÇÎÞ²¡Éú´æÆÚ£¨DFS£©¡£Êý¾Ý½ØÖ¹Ê±£¬A×é¡¢B×éºÍC×é1ÄêDFSÂÊ·Ö±ðΪ100%¡¢88%ºÍ93%¡£ÓëEGFRÒõÐÔ»òδ֪Ïà±È£¬EGFRÍ»±äÑôÐÔ»¼Õ߸´·¢Âʸü¸ß¡£Î´·¢Éú¡Ý3¼¶²»Á¼Ê¼þ¡£
ÕªÒª±àºÅ£º98P
Adjuvant aumolertinib in resected EGFR-Mutated Non-Small-Cell Lung Cancer: a multiple-center real-world experience
°¢ÃÀÌæÄḨÖúÖÎÁÆEGFRÍ»±äµÄNSCLC£ºÒ»Ïî¶àÖÐÐÄÕæÊµÊÀ½çÑо¿
×÷Õߣººú¼á½ÌÊÚ£¨Õã½´óѧҽѧԺ¸½ÊôµÚÒ»Ò½Ôº£©
¼ò½é£º±¾Ñо¿Ö¼ÔÚÆÀ¹ÀNSCLC»¼ÕßÊõºóʹÓð¢ÃÀÌæÄḨÖúÖÎÁƵij¤ÆÚÁÆÐ§ºÍ°²È«ÐÔ¡£¹²ÄÉÈë215ÀýI¨CIIIÆÚ¡¢¾ßÓÐEGFRÍ»±ä¡¢¾¹ý¸ùÖÎÊÖÊõºóµÄ·ÇСϸ°û·ÎÏÙ°©»¼Õß¡£½ÓÊܰ¢ÃÀÌæÄá110 mg/dÖÎÁÆ£¬ÆÀ¹ÀDFS¡¢°²È«ÐÔºÍÄÍÊÜÐÔ¡£ËùÓл¼Õß¾ùËæ·Ã6¸öÔÂÒÔÉÏ£¬40Àý»¼ÕßËæ·Ã2ÄêÒÔÉÏ¡£Êý¾Ý½ØÖ¹Ê±£¬ËùÓл¼Õß¾ùδ³öÏÖÖÐÊàÉñ¾ÏµÍ³×ªÒÆ£¬Ö»ÓÐ1Àý»¼Õß³öÏÖ¹Ç×ªÒÆ¡£2ÄêDFSÂÊ´ï99%¡£Î´·¢Éú¡Ý3¼¶²»Á¼Ê¼þ£¬°²È«ÐÔÁ¼ºÃ¡£
ÕýÔÚ½øÐÐÖеÄÁÙ´²Ñо¿
ÕªÒª±àºÅ£º80TiP
High-dose Aumolertinib Versus Osimertinib in EGFR T790M+ NSCLC Patients With Brain Metastases (ATTACK)
¸ß¼ÁÁ¿°¢ÃÀÌæÄá¶Ô±È°ÂÏ£ÌæÄáÖÎÁÆEGFR T790M+ NSCLCÄÔ×ªÒÆ»¼Õߣ¨ATTACK£©
×÷ÕߣºÂ½Ë´½ÌÊÚ£¨ÉϺ£ÊÐÐØ¿ÆÒ½Ôº£©
¼ò½é£ºATTACKÑо¿£¨NCT04870190£©ÊÇÒ»Ïî¶àÖÐÐÄ¡¢Ëæ»ú¶ÔÕÕ¡¢¿ª·ÅµÄÁÙ´²Ñо¿£¬Ö¼ÔÚÒ»/¶þ´úEGFR-TKIÖÎÁƽøÕ¹ºóµÄEGFR T790MÍ»±äÑôÐÔÍíÆÚNSCLC°éÄÔ×ªÒÆ»¼ÕßÖУ¬ÆÀ¼Û¸ß¼ÁÁ¿°¢ÃÀÌæÄá¶Ô±È°ÂÏ£ÌæÄáµÄÁÆÐ§ºÍ°²È«ÐÔ¡£ÄâÄÉÈë232Àý»¼Õߣ¬°´1:1µÄ±ÈÀýËæ»ú·ÖÅäµ½¸ß¼ÁÁ¿£¨165mg£©°¢ÃÀÌæÄáÖÎÁÆ×é»ò°ÂÏ£ÌæÄáÖÎÁÆ×é¡£Ö÷ÒªÖÕµãΪiPFS£¬´ÎÒªÖÕµã°üÀ¨iORR¡¢ÂÄÚDCR£¨iDCR£©¡¢ÂÍâPFS£¨ePFS£©¡¢ÂÍâORR£¨eORR£©¡¢ÂÍâDCR£¨eDCR£©¡¢PFS¡¢ORR¡¢DCR¡¢OSºÍ°²È«ÐÔ¡£
ÕªÒª±àºÅ£º104TiP
MRD Evaluation of Aumolertinib in EGFR Mutation-positive stage IB and stage IA2-3 NSCLC After Complete Surgical Resection: A Multicenter, Open-lable, Single-arm Study (ASSIST)
MRDÆÀ¹À¼×»ÇËá°¢ÃÀÌæÄáÓÃÓÚEGFRÍ»±äÑôÐÔµÄIBÆÚºÍIA2-3ÆÚ½þÈóÐÔNSCLCÊõºó¸¨ÖúÖÎÁƵĶàÖÐÐÄ¡¢¿ª·Å¡¢µ¥±ÛÁÙ´²Ñо¿£¨ASSIST£©
×÷Õߣº³Ì³¬½ÌÊÚ£¨ÖÐɽ´óѧ¸½ÊôµÚÒ»Ò½Ôº£©
¼ò½é£ºASSISTÑо¿£¨ChiCTR2200063184£©Ö¼ÔڱȽÏ΢С²ÐÁô²¡ÔMRD£©ÑôÐÔºÍMRDÒõÐÔ»¼ÕßʹÓð¢ÃÀÌæÄá³ÖÐøÖÎÁƵÄDFS²îÒ죬²¢Ì½Ë÷»ùÓÚMRD¾«×¼¼ì²â¶Ô¸öÌ廯¸¨Öú°ÐÏòÖÎÁƵÄÖ¸µ¼×÷Óá£ÄâÄÉÈë130ÀýEGFRÍ»±äµÄIBÆÚ»òIA2-3ÆÚNSCLCÊõºó»¼Õߣ¬½ÓÊܰ¢ÃÀÌæÄá110 mg¸¨ÖúÖÎÁÆ¡£¸ù¾ÝÊõºóÁ½´ÎMRD¼ì²â½á¹û½øÐзֲ㣬ÎÞÂÛMRDÑôÐÔ»¹ÊÇMRDÒõÐÔ»¼Õߣ¬¾ù¸øÓè³ÖÐøµÄ°¢ÃÀÌæÄáÖÎÁÆ¡£Ñо¿Ö÷ÒªÖÕµãΪ3ÄêDFSÂÊ£¬´ÎÒªÖÕµã°üÀ¨4ÄêºÍ5ÄêDFSÂÊ¡¢OSºÍ°²È«ÐÔ¡£
Äú¿ÉµÇ¼ÒÔÏÂÍøÖ·£¬²é¿´2023 ELCCÄê»áÑо¿³É¹ûµÄÏêϸÐÅÏ¢£º
https://cslide.ctimeetingtech.com/elcc23hybrid/attendee/confcal_1/presentation/list